In the present study, we hypothesized that targeting STAT3 would be most efficacious in BLCA tumors harboring SMARCB1 deficiency defined as SMARCB1 copy number loss associated with decreased SMARCB1 mRNA expression. This evidence concerns the gene SMARCB1 and bladder transitional cell carcinoma.